Benjamin L. Ebert, USA, receives this year’s Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals.
17 February, 2021
Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2. Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations
16 February, 2021